Anavex Life Sciences Corp (AVXL)

[frrol]

The OLE data will be important as support for the 2b/3 trial results, and we hope to use it in our NDA since the FDA likely will want to see more evidence from us (possibly the EMA as well).

Regarding alpha-synuclein, it was not "discovered by MJF last year." It has been under study for PD for over a decade by many research groups and companies (BP, as well as smaller biotechs like Annovis), and there are ten or more clinical trials currently in progress that target it.